Advisory: Stories on US FDA approving injectable Roche multiple sclerosis therapy are withdrawn
13/09/2024 03:48
Sept 13 (Reuters) - Stories on Roche receiving FDA
approval for an injectable version of its multiple sclerosis
therapy are incorrect and are withdrawn. There will be no
replacement story.
STORY_NUMBER: L4N3KU24Z
STORY_DATE: 13/09/2024
STORY_TIME: 0024 GMT
STORY_NUMBER: L4N3KU255
STORY_DATE: 13/09/2024
STORY_TIME: 0040 GMT
Recent news on Halozyme Therapeutics
See all newsUS RESEARCH ROUNDUP-BlackRock, Evercore, Goldman Sachs
Halozyme wins court order to block Merck's injected Keytruda in select European markets (updated)
US STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
Halozyme wins court order to block Merck's injected Keytruda in select European markets